Synpromics is today unveiling its novel drug-regulatable promoter platform at the European Society of Cell and Gene Therapy (ESGCT) congress in Lausanne, Switzerland. The company is showcasing data generated from its innovative liver inducible and repressible synthetic promoter systems that are tightly controlled by FDA-approved small molecule drugs.

Synpromics has focused on creating a promoter system that is controlled solely by the presence of small molecules, either inducers or repressors, without the use of a trans-activator which is usually required to mediate the desired effect. The company has used its PromPT® platform to identify endogenous tissue specific transcription machinery that can tightly control gene expression when used in combination with an inducer or repressor. The simple mechanisms identified have several advantages over the currently-used two component system, including decreased size and ease of use.

Dr Michael Roberts, CSO and Founder of Synpromics, said: “The creation of drug-inducible and repressible promoters is the ultimate goal of gene therapy, as it should allow accurate and tunable control of the target therapeutic gene. We have significantly advanced our platform by creating a regulatable system that does not rely on the co-expression of other immunogenic regulatory proteins, a limitation that restricts the use of other regulatable promoter systems in gene therapy.”

Synpromics is presenting this development in a poster at the ESGCT congress which describes an inducible system where increased concentrations of the inducer drug result in higher levels of gene expression, and a repressible system where a particular drug concentration can effectively silence the promoter. This tunable system looks set to revolutionise the sector, by enabling tighter regulation of any given therapeutic gene in all manner of liver-targeted gene therapies.

For further information, contact:

Corporate Contact:
Dr Michael L Roberts, CSO and Founder

Synpromics Ltd
T: +44 (0)131 651 9662
E: Michael.roberts@synpromics.com

PR Contact:
Deborah Cockerill / Juliette Craggs
Sciad Communications Ltd
T: +44 (0)20 7470 8801
E: synpromics@sciad.com

For more information about Synpromics please visit www.synpromics.com